## Exhibit 11

State of California ex rel. Ven-A-Care of the Florida Keys, Inc. v. Abbott Labs, Inc. et al., Civil Action No. 03-11226-PBS

Exhibit to the November 25, 2009 Declaration of Philip D. Robben in Support of Defendants' Joint Motion for Partial Summary Judgment

December 3, 2008

1	INITEED GENERAL DIGERRICH COURS	Page 1
1	UNITED STATES DISTRICT COURT	
2	DISTRICT OF MASSACHUSETTS	
3	X	
4	IN RE PHARMACEUTICAL INDUSTRY )	
5	AVERAGE WHOLESALE PRICE ) MDL No. 1456	
6	LITIGATION )	
7	X	
8	THIS DOCUMENT RELATES TO ) Civil Action:	
9	State of California, ex rel. ) 01-12258-PBS	
10	Ven-A-Care v. Abbott )	
11	Laboratories, Inc., et al. )	
12	X	
13	000	
14	WEDNESDAY, DECEMBER 3, 2008	
15	000	
16	VIDEOTAPED DEPOSITION OF	
17	THE CALIFORNIA DEPARTMENT OF HEALTH CARE SERVICES	
18	by J. KEVIN GOROSPE, Pharm.D.	
19	000	
20		
21	Reported By: CAROL NYGARD DROBNY, CSR No. 4018	
22	Registered Merit Reporter	

December 3, 2008

Page 184

- 1 Q. -- for that.
- Just to set the stage, you work today
- 3 for the Department of Health Care Services of the
- 4 State of California; is that correct?
- 5 A. That is correct.
- 6 Q. And that Department administers the
- 7 California Medicaid program, which is also known
- 8 as Medi-Cal; is that right?
- 9 A. That's correct.
- 10 Q. And you are the -- currently the Chief
- 11 of Medi-Cal Pharmacy Policy?
- 12 A. I'm Chief of the Medi-Cal Pharmacy
- 13 Policy Branch.
- Q. Okay. And have you been -- held that
- 15 position since 2000?
- 16 A. Essentially, yes.
- 17 There was a reorganization in -- in
- 18 2007, which changed the structure of the
- 19 Department, and -- and the different division,
- 20 but essentially I've been Chief of the Pharmacy
- 21 Policy since 2000.
- Q. Okay. And do I understand correctly

December 3, 2008

1	know, roughly, are covered by the pharmacy	Page 192
2	program?	
3	A. In any single quarter the number of	
4	NDCs ranges from approximately 20 to 26,000.	
5	Q. 20,000 to 26,000?	
6	A. That's correct.	
7	Q. Okay. And are these manufactured by a	
8	large number of drug manufacturers?	
9	A. Yes.	
10	Q. Do you have any general estimate of	
11	approximately how many manufacturers are	
12	represented by these 20,000 to 26,000 NDCs?	
13	A. Over 300 different labelers.	
14	Q. In terms of expenditures for drugs,	
15	which do brand drugs account for more or less	

- 17 A. In terms of gross expenditures,
- 18 payments to pharmacies?

than multisource drugs?

- 19 Q. Yes.
- A. Is that what you're talking about?
- 21 Q. Yep.
- 22 A. They -- single source and innovator

16

December 3, 2008

Page 193

- 1 multiple source products account for
- 2 approximately 80 percent of the expenditure.
- Q. And when you say "single source or
- 4 multisource innovators, " is that -- are those
- 5 descriptions commonly referred to, at least in
- 6 lay terms, as "brand drugs"?
- 7 A. Yes.
- 8 Q. Okay. And I take it then generic drugs
- 9 or multisource noninnovator drugs make up for
- 10 about 20 percent of pharmacy program
- 11 expenditures?
- 12 A. That's correct.
- 13 Q. Approximately how many claims for
- 14 reimbursement are submitted and processed by
- 15 Medi-Cal?
- 16 And I don't know whether to ask per
- 17 month or year.
- 18 A. Currently or pre -- you want pre Part D
- 19 or post Part D?
- 20 Q. Let's start with currently --
- 21 A. Okay.
- 22 Q. -- and then I want to ask you --